New Weight-Loss drug candidate enters early human testing
NCT ID NCT07399678
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug called ALV-100 in 180 adults who are overweight or obese, with or without type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. Participants receive either the drug or a placebo, and researchers will monitor side effects and measure drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Clinical Pharmacology of Miami
RECRUITINGMiami, Florida, 33172, United States
-
Ohio Clinical Trials
RECRUITINGColumbus, Ohio, 43212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?